AFFINITY ASSET ADVISORS LLC
Q3 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001773195
· CRD 312788
· SEC-registered investment adviser
$355.5M Reported Value Total
AFFINITY ASSET ADVISORS, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $553,053,373, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $2.5B gross asset value
Hedge Fund: $2.4B · Private Equity Fund: $59.7M · Venture Capital Fund: $10.8M
Source: Form ADV filed 2026-07-27
Reported value
$355.5M
Quarter over quarter
-11.1%
Holdings
68
Top-10 concentration
43.4%
Key People
Form ADV owners & control persons
Michael Cho
CO-FOUNDER, MANAGING PARTNER AND PORTFOLIO MANAGER | MANAGING MEMBER
Jonathan Bo-Shing Chu
CO-FOUNDER | MEMBER
Daniel Barry Heller
CHIEF INVESTMENT OFFICER | MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2023 13F record
Q3 2023 13F filing summary
| Period of report | September 30, 2023 |
|---|---|
| Filed | November 14, 2023 |
| Form | 13F-HR |
| Reported value | $355.5M |
| Positions | 68 |
| Change in reported value | +24.2% |
| New positions | 23 |
| Exited positions | 16 |
| Position turnover | 46.4% |
| Top-10 concentration | 43.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 13, 2026
|
101 | $2.2B |
|
Q1 2026 13F
Filed May 14, 2026
|
92 | $1.9B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
82 | $1.8B |
|
Q3 2025 13F
Filed Nov 13, 2025
|
82 | $1.1B |
|
Q2 2025 13F
Filed Aug 13, 2025
|
74 | $732.2M |
|
Q1 2025 13F
Filed May 14, 2025
|
78 | $1.0B |
|
Q4 2024 13F
Filed Feb 13, 2025
|
71 | $746.0M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
73 | $732.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
81 | $867.5M |
|
Q1 2024 13F
Filed May 14, 2024
|
73 | $807.8M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
70 | $547.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
68 | $355.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
59 | $286.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
59 | $303.0M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
50 | $255.0M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
42 | $358.3M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
36 | $237.2M |
|
Q1 2022 13F
Filed May 13, 2022
|
44 | $625.0M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
44 | $275.4M |
|
Q3 2021 13F
Filed Nov 12, 2021
|
64 | $396.0M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | $22.3M | 6.26% |
| 2 | TEVA TEVA PHARMACEUTICAL INDS LTD | $20.4M | 5.74% |
| 3 | CBAY CYMABAY THERAPEUTICS INC | $16.8M | 4.74% |
| 4 | BBIO 2.5 03/15/27 BRIDGEBIO PHARMA INC | $16.4M | 4.62% |
| 5 | CERE CEREVEL THERAPEUTICS HLDNG I | $15.0M | 4.21% |
| 6 | ACLX ARCELLX INC | $14.4M | 4.04% |
| 7 | CRNX CRINETICS PHARMACEUTICALS IN | $13.4M | 3.76% |
| 8 | MDGL MADRIGAL PHARMACEUTICALS INC | $12.4M | 3.49% |
| 9 | ESTA ESTABLISHMENT LABS HLDGS INC | $11.7M | 3.3% |
| 10 | IMVT IMMUNOVANT INC | $11.5M | 3.24% |
| 11 | TEVA C TEVA PHARMACEUTICAL INDS LTD | $11.2M | 3.16% |
| 12 | XENE XENON PHARMACEUTICALS INC | $10.3M | 2.89% |
| 13 | KURA KURA ONCOLOGY INC | $7.8M | 2.2% |
| 14 | ATXS ASTRIA THERAPEUTICS INC | $7.5M | 2.1% |
| 15 | ARKG P ARK ETF TR | $7.0M | 1.96% |
| 16 | ESTA C ESTABLISHMENT LABS HLDGS INC | $6.9M | 1.93% |
| 17 | CYTK CYTOKINETICS INC | $6.8M | 1.91% |
| 18 | KRYS KRYSTAL BIOTECH INC | $6.7M | 1.88% |
| 19 | CNTA CENTESSA PHARMACEUTICALS PLC | $6.6M | 1.85% |
| 20 | MORF MORPHIC HLDG INC | $6.2M | 1.74% |
Values as reported on the Q3 2023 Form 13F. Every position is in the holdings table below.